Early postoperative recovery after peri-acetabular osteotomy: A double-blind, randomised single-centre trial of 48 vs. 8 mg dexamethasone
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2021;9(9):16 Eur J Anaesthesiol. 2021 Mar 1;38(Suppl 1): S41-S49Riassunto dello studio
Sixty-four patients undergoing a peri-acetabular osteotomy were randomized to receive a standard 8mg pre-operative dose of intravenous dexamethasone (n=32) or 48mg of pre-operative dexamethasone (n=32). The primary outcome of interest was incidence of moderate to severe pain (a score >3 on a 10 point Numeric Rating Scale [NRS]) in the PACU. Secondary outcomes included the following: average and maximum pain in the immediate postoperative phase, incidence of complications requiring treatment in the PACU (i.e., nausea and circulatory or respiratory events), incidence of sedation in the PACU, length of stay in the PACU, length of hospital stay, opioid usage in oral morphine equivalents (OMEQs), usage of antiemetic treatment up to 4 days follow-up, incidence of complications requiring treatment during the 1st day, incidence of adverse events at 60-hours follow-up, incidence of any complications, and incidence of readmissions up to 30 days. Tertiary outcomes included the following self-reported measures: average and worst pain using a NRS, incidence of average and worst nausea and vomiting, quality of sleep (i.e., good, difficulty falling asleep, frequent awakenings, or no sleep), and the incidence of feeling sad, restless or fatigued, which were all measured at day 0 to 4 days post-surgery. Results demonstrated that moderate to severe pain using NRS was similar between the 8mg group and 48mg group, with no statistically significant difference observed (66% vs. 75%; p=0.585). Furthermore, no statistically significant difference was observed for any of the secondary outcomes except for cumulative opioid usage in OMEQs, in which a statistical significant difference was observed favoring the 48mg dexamethasone group compared to standard dose (p=0.034) at 4 days post-surgery. Opioid usage was statistically significantly reduced at day 1 post-surgery in the 48mg group vs standard dose group (p=0.044). All tertiary outcomes were also not statistically significantly different between the 2 dosage groups except for quality of sleep, whereby statistically significantly more patients reported restlessness in the 48mg group vs 8mg group (p=0.042). No complications in the 1st 30 days post-surgery were observed. 1 patient reported a serious adverse event in the standard dose group.
Sblocca il Rapporto ACE completo
Ha accesso a 4 altri articoli GRATUITI questo mese.
Clicchi qui sotto per sbloccare e visualizzare questo ACE Reports
Sblocca ora
Valutazioni critiche dei più recenti studi randomizzati controllati ad alto impatto e revisioni sistematiche in ortopedia.
Accesso ai contenuti del podcast OrthoEvidence, comprese le collaborazioni con il Journal of Bone and Joint Surgery, le interviste con chirurghi di fama internazionale e le tavole rotonde sulle novità e gli argomenti ortopedici
Abbonamento a The Pulse, una newsletter bisettimanale basata sulle evidenze scientifiche, progettata per aiutarla a prendere decisioni cliniche migliori.
Accesso esclusivo ad articoli di contenuto originale, tra cui revisioni sistematiche interne, e articoli sui metodi di ricerca sanitaria e su argomenti ortopedici scottanti.
Oppure faccia l'upgrade oggi stesso e acceda a tutti i contenuti di OrthoEvidence a soli 1,99$ a settimana.
Ha già un account? Effettui il login
È affiliato ad una delle nostre associazioni partner?
Clicchi qui per ottenere l'accesso gratuito tra i vantaggi dei membri della sua associazione!
Si abboni a "L'Impulso"
Ortopedia basata sull'evidenza direttamente nella sua casella di posta elettronica. ABBONARSI